Cancer Drug Price Cap: 30% Margin

What the 30% cap changes for patients

The Indian government has capped trade margins on 137 non-scheduled anti-cancer drugs at 30% to reduce treatment costs.

Experts say that drugs make up around 50-70% of the costs of cancer care.

High costs of treatments such as targeted therapies and immunotherapy can lead many patients to defer treatment, opt for cheaper but less effective alternatives or give it up altogether.

Who is affected by the new slab

Cancer is said to be India’s leading cause of catastrophic health spending.

India’s out-of-pocket share for cancer care — estimated by various studies to be 50%-80% of direct treatment costs — is far higher than in most high-income systems.

By the numbers

• ₹2,500 crore: estimated annual savings for patients
• 30%: capped trade margin on non-scheduled anti-cancer drugs
• 137: number of non-scheduled anti-cancer drugs affected by the cap
• 50%-80%: out-of-pocket share for cancer care in India

How the cap will be implemented

The National Pharmaceutical Pricing Authority (NPPA) will set a common trade-margin ceiling on a broad range of cancer medicines.

Manufacturers are required to report formulation-level information, including brand name, composition, pack size, and revised MRP.

What experts say

Experts argue that the permitted margin — which amounts to 42.8% of the price to stockist — is a sizeable mark-up, especially for expensive drugs.

“Any intervention to lower the prices of cancer drugs is a welcome step,” says Sarojini Nadimpally.

Beyond medicines

Medicines are only a part of the bill.

Other expensive components of treatment — diagnostic tests, surgery, radiotherapy, hospital accommodation, consumables, consultations, drug administration and associated clinical services — also need to be addressed.

Challenges in implementation

The government’s decision to cap trade margins on non-scheduled anti-cancer drugs is a step in the right direction, but its implementation poses several challenges.

One of the major challenges is ensuring that the benefits of the price cap are passed on to the patients.

Hospitals and dealers may not pass on the savings to patients, and there is no mechanism to monitor this.

Read also: Google Fitbit Health Updates Explained

Read also: Stroke effects - What happens inside the brain

Way forward

To make cancer treatment more affordable, the government needs to take a holistic approach.

This includes not only controlling the prices of medicines but also reducing the costs of other components of treatment.

A comprehensive healthcare policy that addresses the needs of cancer patients is essential to make a significant impact on the affordability of cancer treatment.

Impact on patients and the healthcare system

The price cap is expected to benefit thousands of cancer patients in India who are struggling to afford expensive treatments.

However, the impact of the price cap on the healthcare system as a whole is still uncertain.

Some experts argue that the price cap could lead to a reduction in the quality of care, as hospitals and healthcare providers may struggle to maintain their profit margins.

Role of the government and regulatory bodies

The government and regulatory bodies, such as the NPPA, play a crucial role in ensuring that the price cap is implemented effectively.

The government needs to monitor the prices of cancer drugs and ensure that the benefits of the price cap are passed on to the patients.

Additionally, the government needs to take steps to address the other components of treatment, such as diagnostic tests and hospital accommodation, to make cancer care more affordable.